Response to Gefitinib in Pericardial Effusion Due to Lung Cancer Cited by

Acta Medica > Archive > 2003, Vol. 46 > Issue 4 > p. 215 > Cited by

Acta Med. 2003, 46: 215-216

https://doi.org/10.14712/18059694.2019.37

Norihiro Kikuchi, Hiroaki Satoh, Takahide Kodama, Norihiro Haraguchi, Kiyohisa Sekizawa

University of Tsukuba, Institute of Clinical Medicine, Division of Respiratory Medicine, Japan

Received June 1, 2003
Accepted July 1, 2003

Lestuzzi Chiara, Berretta Massimiliano, Tomkowski Witold: 2015 update on the diagnosis and management of neoplastic pericardial disease. Expert Review of Cardiovascular Therapy 2015, 13, 377. <https://doi.org/10.1586/14779072.2015.1025754>
Inoue Akira, Kobayashi Kunihiko, Usui Kazuhiro, Maemondo Makoto, Okinaga Shoji, Mikami Iwao, Ando Masahiro, Yamazaki Koichi, Saijo Yasuo, Gemma Akihiko, Miyazawa Hitoshi, Tanaka Tomoaki, Ikebuchi Kenji, Nukiwa Toshihiro, Morita Satoshi, Hagiwara Koichi: First-Line Gefitinib for Patients With Advanced Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy. JCO 2009, 27, 1394. <https://doi.org/10.1200/JCO.2008.18.7658>